Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander M.M. Eggermont, Caroline Robert, Stéphane Dalle et al.|European Journal of Cancer|2024Cited by 84
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A. Ascierto, James Larkin, Michele Del Vecchio et al.|New England Journal of Medicine|2025Cited by 21
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey S. Weber, James Larkin, Michele Del Vecchio et al.|Journal of Clinical Oncology|2024Cited by 9